Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).
Medulloblastoma is a rare but devastating childhood brain cancer. This cancer can spread through the spinal fluid and be deposited elsewhere in the brain or spine.
Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.
An innovative new technique that encourages cancer cells in the kidneys to self-destruct could revolutionize the treatment of the disease, a new study in the journal Pharmaceutics reports.
Cancers that are resistant to radiotherapy could be rendered susceptible through treatment with immunotherapy, a new study suggests.
New research and analysis appearing in the Journal of the Academy of Nutrition and Dietetics, published by Elsevier, highlights the barriers cancer survivors face in maintaining a healthy diet, as well as the role nutrition may play in cancer risk and treatment.
CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.
Cancer is one of the world's greatest health afflictions because, unlike some diseases, it is a moving target, constantly evolving to evade and resist treatment.
Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies.
The term leukaemia is used to describe a group of malignant diseases of the haematopoietic system, in which precursors of the white blood cells (leucocytes) proliferate uncontrollably.
Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease.
A new study by scientists at UNC Lineberger Comprehensive Cancer Center and colleagues published Oct. 30, 2020, in Science, showed that mice exposed to potentially lethal levels of total body radiation were protected from radiation damage if they had specific types of bacteria in their gut.
Scientists have revealed the molecular mechanism regulating the trafficking of lysosomes that increases the invasiveness of radioresistant cancer cells following radiotherapy.
Prostate cancer is the most common type of cancer among American men after skin cancer, but the disease does not affect all races equally.
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.
Loved or hated, the humble oat could be the new superfood for cancer patients as international research shows a diet rich in fiber could significantly reduce radiation-induced gut inflammation.
Radiotherapy is a cornerstone of today's cancer treatment. About half of all people suffering from cancer with a so-called radiotherapy.
A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.
More than 200 genes with novel and known roles in glioblastoma - the most aggressive type of brain cancer - offer promising new drug targets.
A lower total dose of radiotherapy delivered in fewer but larger doses is as safe in the long term as breast cancer radiotherapy courses giving multiple small doses, according to the final results of a 10-year study.
A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas.